PT3177307T - Proteínas de fusão de interleucina-2/recetor alfa de interleucina-2 e métodos de utilização - Google Patents

Proteínas de fusão de interleucina-2/recetor alfa de interleucina-2 e métodos de utilização

Info

Publication number: PT3177307T
Authority: PT; Portugal
Prior art keywords: interleukin; methods; fusion proteins; receptor alpha; alpha fusion
Prior art date: 2014-08-06

Application number

PT157505603T

Other languages

English (en)

Original Assignee

The Univ Of Miami

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-08-06

Filing date

2015-08-05

Publication date

2024-09-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53836871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3177307(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-08-05 Application filed by The Univ Of Miami filed Critical The Univ Of Miami

2024-09-13 Publication of PT3177307T publication Critical patent/PT3177307T/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Diabetes (AREA)
Cell Biology (AREA)
Neurology (AREA)
Virology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Obesity (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Endocrinology (AREA)

PT157505603T 2014-08-06 2015-08-05 Proteínas de fusão de interleucina-2/recetor alfa de interleucina-2 e métodos de utilização PT3177307T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201462033726P	2014-08-06	2014-08-06

Publications (1)

Publication Number	Publication Date
PT3177307T true PT3177307T (pt)	2024-09-13

Family

ID=53836871

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT157505603T PT3177307T (pt)	2014-08-06	2015-08-05	Proteínas de fusão de interleucina-2/recetor alfa de interleucina-2 e métodos de utilização

Country Status (29)

Country	Link
US (2)	US12084483B2 (pt)
EP (2)	EP4438621A2 (pt)
JP (3)	JP6723982B2 (pt)
KR (1)	KR102653758B1 (pt)
CN (2)	CN113912737A (pt)
AU (3)	AU2015301071C1 (pt)
BR (1)	BR112017001940A2 (pt)
CA (1)	CA2957273C (pt)
CL (1)	CL2017000284A1 (pt)
CO (1)	CO2017002166A2 (pt)
DK (1)	DK3177307T3 (pt)
EA (2)	EA202091342A3 (pt)
FI (1)	FI3177307T3 (pt)
IL (2)	IL250007B (pt)
LT (1)	LT3177307T (pt)
MA (2)	MA40721A (pt)
MX (1)	MX2017001062A (pt)
MY (1)	MY180831A (pt)
NZ (2)	NZ728042A (pt)
PE (1)	PE20170503A1 (pt)
PH (1)	PH12017500042A1 (pt)
PT (1)	PT3177307T (pt)
RS (1)	RS65930B1 (pt)
SA (1)	SA517380842B1 (pt)
SG (2)	SG11201700706WA (pt)
SI (1)	SI3177307T1 (pt)
TN (1)	TN2017000020A1 (pt)
WO (1)	WO2016022671A1 (pt)
ZA (1)	ZA201700245B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20140044675A1 (en)	2012-08-10	2014-02-13	Roche Glycart Ag	Interleukin-2 fusion proteins and uses thereof
US11098099B2 (en)	2014-02-06	2021-08-24	Hoffmann-La Roche Inc.	Interleukin-2 fusion proteins and uses thereof
MA40721A (fr)	2014-08-06	2017-06-13	The Univ Of Miami	Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
WO2017201432A2 (en) *	2016-05-19	2017-11-23	Jounaidi Youssef	Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
CN110087681A (zh)	2016-09-28	2019-08-02	佐马美国有限公司	结合白细胞介素-2的抗体和其用途
BR112019018915A2 (pt)	2017-03-15	2020-04-14	Pandion Therapeutics Inc	imunotolerância direcionada
US10676516B2 (en)	2017-05-24	2020-06-09	Pandion Therapeutics, Inc.	Targeted immunotolerance
US10174092B1 (en)	2017-12-06	2019-01-08	Pandion Therapeutics, Inc.	IL-2 muteins
US10946068B2 (en)	2017-12-06	2021-03-16	Pandion Operations, Inc.	IL-2 muteins and uses thereof
CA3084262A1 (en) *	2017-12-06	2019-06-13	The Board Of Trustees Of The Leland Stanford Junior University	Engineered proteins to enhance sensitivity of a cell to il-2
EP3768700A1 (en) *	2018-03-23	2021-01-27	Kite Pharma, Inc.	Chimeric transmembrane proteins and uses thereof
EA202092316A1 (ru) *	2018-03-28	2021-05-25	Бристол-Маерс Сквибб Компани	Слитые белки интерлейкина-2/альфа-рецептора интерлейкина-2 и способы применения
BR112021016962A2 (pt) *	2019-03-18	2021-11-23	Biontech Cell & Gene Therapies Gmbh	Variantes do receptor de interleucina-2 (il2r) e da interleucina-2 (il2) para ativação específica de células efetoras imunes
CN111944036B (zh)	2019-05-14	2024-09-06	上海盖浦生物科技有限公司	一种增殖免疫细胞的突变体蛋白
AU2020279240A1 (en)	2019-05-20	2021-12-23	Pandion Operations, Inc.	MAdCAM targeted immunotolerance
AU2020285636A1 (en) *	2019-05-24	2021-11-04	Proviva Therapeutics (Hong Kong) Limited	IL-2 compositions and methods of use thereof
US20210038684A1 (en) *	2019-06-11	2021-02-11	Alkermes Pharma Ireland Limited	Compositions and Methods for Cancer Immunotherapy
US20220378933A1 (en) *	2019-09-19	2022-12-01	Proviva Therapeutics (Hong Kong) Limited	Il-2 compositions and methods of use thereof
CN114555110A (zh) *	2019-10-18	2022-05-27	奥克梅斯制药爱尔兰有限公司	与免疫检查点抑制剂组合的免疫调节性il-2剂
EP4077397A2 (en)	2019-12-20	2022-10-26	Regeneron Pharmaceuticals, Inc.	Novel il2 agonists and methods of use thereof
WO2021168079A1 (en)	2020-02-21	2021-08-26	Pandion Operations, Inc.	Tissue targeted immunotolerance with a cd39 effector
JP2023524077A (ja)	2020-04-30	2023-06-08	イテオバイオセラピー，インク．	活性可能なｉｌ２の組成物および使用方法
TW202317623A (zh) *	2021-06-14	2023-05-01	美商再生元醫藥公司	基於il2之治療劑及其使用方法
CN118891055A (zh) *	2022-02-11	2024-11-01	穆拉肿瘤公司	用于癌症免疫疗法的组合物和方法
WO2023159135A2 (en) *	2022-02-16	2023-08-24	University Of Miami	Il-2 and tl1a fusion proteins and methods of use thereof
CN114875069B (zh) *	2022-04-22	2023-09-15	四川大学	基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
WO2024175020A1 (en) *	2023-02-22	2024-08-29	Biocytogen Pharmaceuticals (Beijing) Co., Ltd.	Anti-il2ra antibodies and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ201918A (en)	1981-09-18	1987-04-30	Genentech Inc	N-terminal methionyl analogues of bovine growth hormone
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4873192A (en)	1987-02-17	1989-10-10	The United States Of America As Represented By The Department Of Health And Human Services	Process for site specific mutagenesis without phenotypic selection
FR2619719B1 (fr)	1987-09-01	1991-05-10	Sanofi Sa	Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
US5250296A (en) *	1990-11-29	1993-10-05	Takeda Chemical Industries, Ltd.	Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US5605793A (en)	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
US5837458A (en)	1994-02-17	1998-11-17	Maxygen, Inc.	Methods and compositions for cellular and metabolic engineering
DK0796280T3 (da)	1994-12-28	2003-04-22	Univ Kentucky	Murint monoklonalt anti-idiotypisk antistof 3H1
US6967092B1 (en) *	1996-10-25	2005-11-22	Mc Kearn John P	Multi-functional chimeric hematopoietic receptor agonists
DE19701141C1 (de) *	1997-01-16	1998-04-09	Hoechst Ag	Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
DZ2788A1 (fr)	1998-05-15	2003-12-01	Bayer Ag	Agonistes et antagonistes selectifs à IL-2.
CN1596311A (zh)	2001-09-28	2005-03-16	株式会社载体研究所	编码表位结合型β2m且感染哺乳动物细胞的病毒载体及其应用
KR20070003934A (ko)	2004-03-05	2007-01-05	노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드	치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
PT1899364T (pt)	2005-05-17	2020-05-20	Univ Connecticut	Composições e métodos para imunomodulação num organismo
CN101255197B (zh) *	2008-03-28	2012-01-25	浙江海正药业股份有限公司	血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用
GB0815216D0 (en) *	2008-08-21	2008-09-24	Asterion Ltd	Interleukin
US8734774B2 (en) *	2010-04-02	2014-05-27	University Of Rochester	Protease activated cytokines
WO2012088383A2 (en)	2010-12-23	2012-06-28	Genentech, Inc.	PILR alpha INTERACTIONS AND METHODS OF MODIFYING SAME
PT2859015T (pt)	2012-06-08	2018-06-26	Alkermes Inc	Ligandos modificados por permutação circular como agonistas e antagonistas
US20140044675A1 (en) *	2012-08-10	2014-02-13	Roche Glycart Ag	Interleukin-2 fusion proteins and uses thereof
WO2014100913A1 (en)	2012-12-24	2014-07-03	Beijing Anxinhuaide Biotech. Co., Ltd	Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
MA40721A (fr)	2014-08-06	2017-06-13	The Univ Of Miami	Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

2015
- 2015-08-04 MA MA040721A patent/MA40721A/fr unknown
- 2015-08-04 MA MA40094A patent/MA40094B1/fr unknown
- 2015-08-05 LT LTEPPCT/US2015/043792T patent/LT3177307T/lt unknown
- 2015-08-05 FI FIEP15750560.3T patent/FI3177307T3/fi active
- 2015-08-05 NZ NZ728042A patent/NZ728042A/en unknown
- 2015-08-05 MX MX2017001062A patent/MX2017001062A/es unknown
- 2015-08-05 KR KR1020177005686A patent/KR102653758B1/ko active IP Right Grant
- 2015-08-05 BR BR112017001940A patent/BR112017001940A2/pt active Search and Examination
- 2015-08-05 PT PT157505603T patent/PT3177307T/pt unknown
- 2015-08-05 CN CN202110539190.4A patent/CN113912737A/zh active Pending
- 2015-08-05 EP EP24181690.9A patent/EP4438621A2/en active Pending
- 2015-08-05 TN TN2017000020A patent/TN2017000020A1/en unknown
- 2015-08-05 EP EP15750560.3A patent/EP3177307B1/en active Active
- 2015-08-05 SI SI201532026T patent/SI3177307T1/sl unknown
- 2015-08-05 CN CN201580042330.XA patent/CN107074967B/zh active Active
- 2015-08-05 RS RS20240999A patent/RS65930B1/sr unknown
- 2015-08-05 EA EA202091342A patent/EA202091342A3/ru unknown
- 2015-08-05 WO PCT/US2015/043792 patent/WO2016022671A1/en active Application Filing
- 2015-08-05 DK DK15750560.3T patent/DK3177307T3/da active
- 2015-08-05 NZ NZ766851A patent/NZ766851A/en unknown
- 2015-08-05 SG SG11201700706WA patent/SG11201700706WA/en unknown
- 2015-08-05 MY MYPI2017700387A patent/MY180831A/en unknown
- 2015-08-05 AU AU2015301071A patent/AU2015301071C1/en active Active
- 2015-08-05 JP JP2017506395A patent/JP6723982B2/ja active Active
- 2015-08-05 EA EA201790063A patent/EA035956B1/ru not_active IP Right Cessation
- 2015-08-05 PE PE2017000128A patent/PE20170503A1/es unknown
- 2015-08-05 CA CA2957273A patent/CA2957273C/en active Active
- 2015-08-05 SG SG10201913695PA patent/SG10201913695PA/en unknown
- 2015-08-05 US US15/501,392 patent/US12084483B2/en active Active
2017
- 2017-01-06 PH PH12017500042A patent/PH12017500042A1/en unknown
- 2017-01-09 IL IL250007A patent/IL250007B/en active IP Right Grant
- 2017-01-11 ZA ZA2017/00245A patent/ZA201700245B/en unknown
- 2017-02-03 CL CL2017000284A patent/CL2017000284A1/es unknown
- 2017-02-05 SA SA517380842A patent/SA517380842B1/ar unknown
- 2017-03-03 CO CONC2017/0002166A patent/CO2017002166A2/es unknown
2020
- 2020-05-22 AU AU2020203352A patent/AU2020203352B2/en active Active
- 2020-06-24 JP JP2020108721A patent/JP7272663B2/ja active Active
- 2020-07-09 IL IL275944A patent/IL275944B/en unknown
2022
- 2022-06-10 AU AU2022204034A patent/AU2022204034A1/en not_active Abandoned
- 2022-08-25 US US17/822,333 patent/US20230079120A1/en active Pending
2023
- 2023-04-20 JP JP2023069282A patent/JP2023099045A/ja active Pending

Also Published As

Publication number	Publication date
US20170233448A1 (en)	2017-08-17
AU2015301071C1 (en)	2020-07-02
IL250007B (en)	2020-07-30
MX2017001062A (es)	2017-07-14
NZ766851A (en)	2024-07-26
IL275944B (en)	2022-02-01
MA40721A (fr)	2017-06-13
SA517380842B1 (ar)	2021-12-26
US20230079120A1 (en)	2023-03-16
BR112017001940A2 (pt)	2017-11-28
KR20170030646A (ko)	2017-03-17
AU2020203352B2 (en)	2022-03-10
PH12017500042A1 (en)	2017-05-22
EP3177307A1 (en)	2017-06-14
CN107074967B (zh)	2021-06-08
ZA201700245B (en)	2024-06-26
NZ728042A (en)	2024-07-26
SI3177307T1 (sl)	2024-09-30
EA035956B1 (ru)	2020-09-04
IL275944A (en)	2020-08-31
SG10201913695PA (en)	2020-03-30
PE20170503A1 (es)	2017-05-11
IL250007A0 (en)	2017-03-30
AU2015301071B2 (en)	2020-03-05
WO2016022671A1 (en)	2016-02-11
EA201790063A1 (ru)	2017-06-30
US12084483B2 (en)	2024-09-10
AU2015301071A1 (en)	2017-02-02
CL2017000284A1 (es)	2017-11-17
MA40094A1 (fr)	2021-09-30
KR102653758B1 (ko)	2024-04-04
EA202091342A3 (ru)	2020-12-30
CN113912737A (zh)	2022-01-11
EP3177307B1 (en)	2024-07-17
JP2017523789A (ja)	2017-08-24
JP2021000084A (ja)	2021-01-07
MY180831A (en)	2020-12-10
MA40094B1 (fr)	2022-05-31
FI3177307T3 (fi)	2024-10-04
AU2022204034A1 (en)	2022-07-14
AU2020203352A1 (en)	2020-07-02
JP7272663B2 (ja)	2023-05-12
CA2957273C (en)	2023-03-14
LT3177307T (lt)	2024-08-12
CA2957273A1 (en)	2016-02-11
RS65930B1 (sr)	2024-10-31
EP4438621A2 (en)	2024-10-02
JP2023099045A (ja)	2023-07-11
CO2017002166A2 (es)	2017-05-19
EA202091342A2 (ru)	2020-11-30
CN107074967A (zh)	2017-08-18
SG11201700706WA (en)	2017-02-27
TN2017000020A1 (en)	2018-07-04
JP6723982B2 (ja)	2020-07-15
DK3177307T3 (da)	2024-10-07

Publication	Publication Date	Title
IL275944B (en)	2022-02-01	Fusion protein of interleukin-2 and receptor for interleukin-2 alpha and methods of use
HRP20190028T1 (hr)	2019-02-22	Interleukin-2 fuzijski proteini i njihove primjene
IL304178A (en)	2023-09-01	Anti-gitr antibodies and methods of using them
IL279606A (en)	2021-03-01	Anti-TREM2 antibodies and methods of using them
HK1243102A1 (zh)	2018-07-06	抗cd79b抗體和使用方法
GB201509062D0 (en)	2015-07-08	OX40L fusion proteins and uses thereof
IL262727A (en)	2018-12-31	Cd40l-fc fusion polypeptides and methods of use thereof
HUE047784T2 (hu)	2020-05-28	Anti-TIM3 antitestek és alkalmazási eljárások
IL246736B (en)	2020-09-30	Anti-jagged1 antibodies and methods of use
EP3092248A4 (en)	2017-06-28	Fusion polypeptides and methods of use
HK1244534A1 (zh)	2018-08-10	重組疏螺旋體蛋白及其使用方法
EP3164419C0 (en)	2024-07-24	ANTI-BRDU ANTIBODIES AND METHODS OF USE
EP3322736A4 (en)	2019-02-20	FUSION POLYPEPTIDES AND METHOD OF USE